New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
September 22, 2023 - The FDA approved Fabre-Kramer Pharmaceuticals’ Exxua (gepirone), for the treatment of major depressive disorder (MDD) in adults.
Download PDF
Return to publications
